Recce Pharmaceuticals Ltd
ASX:RCE

Watchlist Manager
Recce Pharmaceuticals Ltd Logo
Recce Pharmaceuticals Ltd
ASX:RCE
Watchlist
Price: 0.58 AUD 4.5%
Market Cap: 167.7m AUD

Relative Value

The Relative Value of one RCE stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.58 AUD, Recce Pharmaceuticals Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RCE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
57
vs Industry
16
Median 3Y
17.7
Median 5Y
31.3
Industry
2.6
Forward
19.5
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-8.6
Industry
21.6
Forward
-6.4
vs History
vs Industry
17
Median 3Y
-10.4
Median 5Y
-18.5
Industry
16.5
vs History
vs Industry
13
Median 3Y
-12.8
Median 5Y
-16.6
Industry
22.5
vs History
vs Industry
0
Median 3Y
-13
Median 5Y
8.1
Industry
2.3
vs History
57
vs Industry
15
Median 3Y
17.3
Median 5Y
30.7
Industry
2.9
Forward
19.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-8.7
Industry
13
Forward
-6.7
vs History
vs Industry
Median 3Y
-6.6
Median 5Y
-8.7
Industry
16.6
Forward
-6.5
vs History
vs Industry
19
Median 3Y
-10
Median 5Y
-16.3
Industry
15.8
vs History
vs Industry
17
Median 3Y
-9.8
Median 5Y
-16.2
Industry
19.1
vs History
vs Industry
0
Median 3Y
-77.2
Median 5Y
194.2
Industry
1.9

Multiples Across Competitors

RCE Competitors Multiples
Recce Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Recce Pharmaceuticals Ltd
ASX:RCE
167.3m AUD 21.7 -7.8 -8.2 -8.2
US
Eli Lilly and Co
NYSE:LLY
967.3B USD 16.3 52.5 35.3 37.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
508B USD 5.5 20.2 16.5 21.4
CH
Roche Holding AG
SIX:ROG
252.3B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
208.5B GBP 4.8 29.7 108.3 158.5
CH
Novartis AG
SIX:NOVN
202.4B CHF 4.5 17.7 11.2 14.5
US
Merck & Co Inc
NYSE:MRK
247.7B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.7 9.6 11.2
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
146.6B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average P/E: 23.6
Negative Multiple: -7.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBITDA: 438.7
Negative Multiple: -8.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.3
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.2
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Recce Pharmaceuticals Ltd
ASX:RCE
Average EV/EBIT: 1 881.1
Negative Multiple: -8.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.5
23%
6.9
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
1%
11.2
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
8%
1.3